share_log

Forbes tate partners hires cannabis industry expert Shanita Penny to public affairs practice

Forbes tate partners hires cannabis industry expert Shanita Penny to public affairs practice

福布斯泰特合夥人聘請大麻行業專家Shanita Penny從事公共事務
Benzinga Real-time News ·  2022/04/27 10:14

Bipartisan, full-service government and public affairs advocacy firm, Forbes Tate Partners has hired Shanita Penny as senior vice president of its public affairs and cannabis practices.

兩黨合作的全方位政府和公共事務倡導公司,福布斯泰特合夥公司已經聘請Shanita Penny擔任其公共事務和大麻業務的高級副總裁。

Penny, who has extensive experience as a cannabis professional, small business advocate and entrepreneur, played a crucial role in helping reform cannabis laws and advance equitable policies.

作為一名大麻專業人士、小企業倡導者和企業家,彭尼擁有豐富的經驗,在幫助改革大麻法律和推進公平政策方面發揮了關鍵作用。

"This is a dynamic marketplace, both in terms of the evolving industry and the policy framework impacting the industry at the federal, state and local levels, and there's no team in DC who better understands the interplay between the two." Shanita Penny told Benzinga exclusively.

這是一個充滿活力的市場,無論是就不斷髮展的行業而言,還是就聯邦、州和地方層面影響該行業的政策框架而言,DC中沒有一個團隊能更好地瞭解兩者之間的相互作用。Shanita Penny獨家告訴Benzinga。

She will continue as a senior advisor to the Coalition for Cannabis Policy, Education, and Regulation (CPEAR), which represents issue experts and a vast group of stakeholders from regulated industries committed to establishing a responsible and equitable federal regulatory framework for cannabis in the U.S.

她將繼續擔任大麻政策、教育和管理聯盟(CPEAR),代表問題專家和來自受監管行業的一大批利益攸關方,致力於在美國建立一個負責任和公平的聯邦大麻監管框架。

"I can't think of a better time to welcome a supply chain expert and small business advocate like Shanita Penny to the Forbes Tate team," said founding partner Jeff Forbes. "Her vast knowledge on emerging markets, consumer safety, and competition policy is a boon to our clients as they navigate today's rapidly changing economic environment. I'm also looking forward to the work she will continue to do on reforming cannabis at the federal level and advancing FTP as a thoughtful leader in this space."

“我想不出比這更好的時機來歡迎像Shanita Penny這樣的供應鏈專家和小企業倡導者加入福布斯泰特團隊,”創始合夥人説傑夫·福布斯。她在新興市場、消費者安全和競爭政策方面的豐富知識對我們的客户來説是一種福音,因為他們正在駕馭當今快速變化的經濟環境。我也期待着她將繼續在聯邦一級改革大麻和推動ftp作為這一領域的深思熟慮的領導者所做的工作。

Penny said she was equally enthusiastic to be part of the Forbes Tate team. 

彭妮説,她同樣熱衷於成為福布斯泰特團隊的一員。

"I'm excited to be joining Forbes Tate's accomplished team during an explosion of support for cannabis reform at both the state and federal level," Penny said. "As conversations about federal cannabis regulation progress, I'm eager to provide our clients the counsel necessary to successfully navigate this dynamic landscape. I also look forward to broadening the firm's reach and shaping responsible policies for businesses and consumers alike."

佩妮説:“在州和聯邦兩級對大麻改革的支持激增之際,我很高興能加入福布斯·泰特成功的團隊。”隨着有關聯邦大麻監管的談判取得進展,我渴望為我們的客户提供成功駕馭這一動態格局所需的建議。我也期待擴大公司的覆蓋範圍,為企業和消費者制定負責任的政策。

Before joining FTP, Penny served as president of the Minority Cannabis Business Association (MCBA) where she advocated for social equity policies in the industry, such as increasing diversity, expanding equal access and promoting economic empowerment in communities most impacted by the war on drugs. She has tirelessly lobbied on Capitol Hill with the National Organization for the Reform of Marijuana Laws (NORML) to help reform federal cannabis laws.

在加入ftp之前,Penny曾擔任少數民族大麻商業協會(MCBA),她倡導該行業的社會公平政策,例如增加多樣性,擴大平等機會,並促進受禁毒戰爭影響最大的社區的經濟賦權。她不知疲倦地在國會山與全國大麻法律改革組織(NORML)幫助改革聯邦大麻法律。

Penny founded Budding Solutions, a boutique cannabis consultancy to help clients establish and scale compliant, successful cannabis businesses.

Penny創立萌芽中的解決方案,一家精品大麻諮詢公司,幫助客户建立和擴大合規、成功的大麻業務。

She also co-founded DocHouse, a craft cannabis cultivator and manufacturer acquired by $AYR WELLNESS INC(AYRWF.US)$.

她也是聯合創始人之一DocHouse,一家精湛的大麻種植和製造商,被$Ayr Healness Inc.(AYRWF.US)$.

Penny currently serves on the board of directors for the Alliance for Sensible Markets and on the advisory board of Regennabis and Shoki Beverages.

Penny目前在董事會任職於理性市場聯盟以及Regennabis和Shoki Beverages的顧問委員會成員。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論